Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib

Cheng,Yanhong; Hao,Yingchan; Zhang,Aimei; Hu,Chaojie; Jiang,Xiaoxiao; Wu,Quan; Xu,Xiucai

doi:10.3892/ijmm.2017.3205

Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib

Authors:
- Yanhong Cheng
- Yingchan Hao
- Aimei Zhang
- Chaojie Hu
- Xiaoxiao Jiang
- Quan Wu
- Xiucai Xu
View Affiliations

Affiliations: Central Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001, P.R. China
Published online on: October 20, 2017 https://doi.org/10.3892/ijmm.2017.3205
Pages: 455-463

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The persistent activation of signal transducer and activator of transcription 5 (STAT5) may principally be attributed to breakpoint cluster region (BCR)-Abelson murine leukemia viral oncogene homolog 1 (ABL1), and have multi-faceted effects in the development of chronic myeloid leukemia (CML). The p53 protein network regulates important mechanisms in DNA damage repair, cell cycle regulation/checkpoints, and cell senescence and apoptosis, as demonstrated by its ability to positively regulate the expression of various pro-apoptotic genes, including B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein (Bax). In the present study, it was observed that the mRNA levels of STAT5A and STAT5B were upregulated in patients with imatinib-resistant CML and in the imatinib-resistant K562/G CML cell line. In addition, increased expression of STAT5 was observed in the BCR-ABL1 mutation group, compared with that in the non-BCR-ABL1 mutation group, regardless of patient imatinib resistance state. Elevated levels of reactive oxygen species (ROS) and DNA double-strand breaks were identified in K562/G cells using flow cytometric and phosphorylated H2AX (γ-H2AX) foci immunofluorescence assays, respectively, compared with the imatinib-sensitive K562 cells. The levels of intracellular ROS and γ-H2AX were decreased by the ROS scavenger (N-acetylcysteine), and ROS levels were also markedly reduced by STAT5 inhibitor (SH-4-54). In addition, imatinib significantly inhibited the proliferation of K562 and K562/G cells, with half maximal inhibitory concentration values of 0.17±0.07 and 14.78±0.43 µM, respectively, and the levels of apoptosis were significantly different between K562 and K562/G cells following treatment with imatinib. The mRNA and protein levels of STAT5 and mouse double minute 2 homolog (MDM2) were upregulated, whereas those of Bax were downregulated in K562/G cells, as determined using western blot analysis. Additionally, although the two cell lines exhibited relatively low protein expression levels of p53, lower levels of p53 and TPp53BP1 transcripts were detected in the K562/G cells. Taken together, these findings suggest that the resistance of CML to the tyrosine kinase inhibitor, imatinib, may be associated with persistent STAT5-mediated ROS production, and the abnormality of the p53 pathway.

View Figures

View References

1	Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, et al: Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 30:1044–1054. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, et al: Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study. Leukemia. 30:57–64. 2016. View Article : Google Scholar :
3	Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, et al: Dasatinib first-line: Multicentric Italian experience outside clinical trials. Leuk Res. 40:24–29. 2016. View Article : Google Scholar
4	Hughes TP and Ross DM: Moving treatment-free remission into mainstream clinical practice in CML. Blood. 128:17–23. 2016. View Article : Google Scholar : PubMed/NCBI
5	Vaidya S, Vundinti BR, Shanmukhaiah C, Chakrabarti P and Ghosh K: Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS One. 10:e01148282015. View Article : Google Scholar : PubMed/NCBI
6	Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, et al: The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. 127:1870–1880. 2016. View Article : Google Scholar : PubMed/NCBI
7	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, et al: BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar : PubMed/NCBI
8	Turhan AG: STAT5 as a CML target: STATinib therapies? Blood. 117:3252–3253. 2011. View Article : Google Scholar : PubMed/NCBI
9	Warsch W, Grundschober E and Sexl V: Adding a new facet to STAT5 in CML: Multitasking for leukemic cells. Cell Cycle. 12:1813–1814. 2013. View Article : Google Scholar : PubMed/NCBI
10	Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al: High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 117:3409–3420. 2011. View Article : Google Scholar : PubMed/NCBI
11	Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM and Van Etten RA: Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 119:3550–3560. 2012. View Article : Google Scholar : PubMed/NCBI
12	Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, et al: Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34⁺ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487–30499. 2015. View Article : Google Scholar : PubMed/NCBI
13	Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, et al: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108:28–37. 2006. View Article : Google Scholar : PubMed/NCBI
14	Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al: European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122:872–884. 2013. View Article : Google Scholar : PubMed/NCBI
15	Dong HJ, Zhou LT, Zhu DX, Wang DM, Fang C, Zhu HY, Zhuang Y, Miao KR, Xu W and Li JY: The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol. 90:709–717. 2011. View Article : Google Scholar
16	Lan X, Zhao C, Chen X, Zhang P, Zang D, Wu J, Chen J, Long H, Yang L, Huang H, et al: Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. J Hematol Oncol. 9:1292016. View Article : Google Scholar : PubMed/NCBI
17	Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, et al: Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. Clin Cancer Res. 20:151–163. 2014. View Article : Google Scholar :
18	Wu L, Chen X, Huang L, Tian J, Ke F, Xu J, Chen Y and Zheng M: A Novobiocin derivative, XN4, inhibits the proliferation of chronic myeloid leukemia cells by inducing oxidative DNA damage. PLoS One. 10:e01233142015. View Article : Google Scholar : PubMed/NCBI
19	Ismail IH, Wadhra TI and Hammarsten O: An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans. Nucleic Acids Res. 35:e362007. View Article : Google Scholar : PubMed/NCBI
20	Ren G, Luo W, Sun W, Niu Y, Ma DL, Leung CH, Wang Y, Lu JJ and Chen X: Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells. Phytomedicine. 23:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
21	Maillet A and Pervaiz S: Redox regulation of p53, redox effectors regulated by p53: a subtle balance. Antioxid Redox Signal. 16:1285–1294. 2012. View Article : Google Scholar
22	Banerjee K, Ganguly A, Chakraborty P, Sarkar A, Singh S, Chatterjee M, Bhattacharya S and Choudhuri SK: ROS and RNS induced apoptosis through p53 and iNOS mediated pathway by a dibasic hydroxamic acid molecule in leukemia cells. Eur J Pharm Sci. 52:146–164. 2014. View Article : Google Scholar
23	Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F and Turhan AG: Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 118:3657–3660. 2011. View Article : Google Scholar : PubMed/NCBI
24	Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, et al: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102:276–283. 2003. View Article : Google Scholar : PubMed/NCBI
25	Raja T: Optimizing second-line therapy for chronic myeloid leukemia. Indian J Cancer. 49:46–56. 2012. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A and Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL⁺ progenitors via JAK-2/STAT-5 pathway activation. Blood. 109:2147–2155. 2007. View Article : Google Scholar
27	Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et al: Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
28	Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L, Moriggl R and Sexl V: Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 107:4898–4906. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E, Kantarjian HM and Jones D: Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 27:3642–3649. 2009. View Article : Google Scholar : PubMed/NCBI
30	Mallette FA, Moiseeva O, Calabrese V, Mao B, Gaumont-Leclerc MF and Ferbeyre G: Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence. Ann NY Acad Sci. 1197:142–151. 2010. View Article : Google Scholar : PubMed/NCBI
31	Gorrini C, Harris IS and Mak TW: Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
32	Reczek CR and Chandel NS: ROS-dependent signal transduction. Curr Opin Cell Biol. 33:8–13. 2015. View Article : Google Scholar :
33	Brem R, Li F, Montaner B, Reelfs O and Karran P: DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation. Oncogene. 29:3953–3963. 2010. View Article : Google Scholar : PubMed/NCBI
34	Gu B and Zhu WG: Surf the post-translational modification network of p53 regulation. Int J Biol Sci. 8:672–684. 2012. View Article : Google Scholar : PubMed/NCBI
35	Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, et al: Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 364:2496–2506. 2011. View Article : Google Scholar : PubMed/NCBI
36	Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gäken J, Pennaneach C, Ireland R, Czepulkowski B, et al: TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 160:660–672. 2013. View Article : Google Scholar : PubMed/NCBI
37	Perrotti D, Jamieson C, Goldman J and Skorski T: Chronic myeloid leukemia: Mechanisms of blastic transformation. J Clin Invest. 120:2254–2264. 2010. View Article : Google Scholar : PubMed/NCBI
38	Woo SM, Choi YK, Kim AJ, Cho SG and Ko SG: p53 causes butein mediated apoptosis of chronic myeloid leukemia cells. Mol Med Rep. 13:1091–1096. 2016. View Article : Google Scholar
39	Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 387:296–299. 1997. View Article : Google Scholar : PubMed/NCBI